Barclays’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-1,500
| Closed | -$139K | – | 5826 |
|
|
2021
Q4 | $139K | Buy |
+1,500
| New | +$98.8K | ﹤0.01% | 3658 |
|
|
2018
Q3 | – | Sell |
-30,000
| Closed | -$1.31M | – | 7532 |
|
|
2018
Q2 | $1.31M | Buy |
30,000
+27,000
| +900% | +$1.16M | ﹤0.01% | 2981 |
|
|
2018
Q1 | $119K | Buy |
3,000
+2,440
| +436% | +$94.9K | ﹤0.01% | 5253 |
|
|
2017
Q4 | $19K | Hold |
560
| – | – | ﹤0.01% | 6321 |
|
|
2017
Q3 | $14K | Hold |
560
| – | – | ﹤0.01% | 5981 |
|
|
2017
Q2 | $9K | Hold |
560
| – | – | ﹤0.01% | 6097 |
|
|
2017
Q1 | $8K | Sell |
560
-1,030
| -65% | -$15.3K | ﹤0.01% | 6157 |
|
|
2016
Q4 | $23K | Buy |
1,590
+170
| +12% | +$2.63K | ﹤0.01% | 5568 |
|
|
2016
Q3 | $25K | Sell |
1,420
-30
| -2% | -$498 | ﹤0.01% | 5371 |
|
|
2016
Q2 | $25K | Buy |
1,450
+630
| +77% | +$11.3K | ﹤0.01% | 5188 |
|
|
2016
Q1 | $8K | Sell |
820
-14,720
| -95% | -$236K | ﹤0.01% | 5550 |
|
|
2015
Q4 | $155K | Sell |
15,540
-960
| -6% | -$19.6K | ﹤0.01% | 4110 |
|
|
2015
Q3 | $165K | Sell |
16,500
-2,510
| -13% | -$85.2K | ﹤0.01% | 4283 |
|
|
2015
Q2 | $760K | Buy |
19,010
+120
| +0.6% | +$5.21K | ﹤0.01% | 3119 |
|
|
2015
Q1 | $756K | Sell |
18,890
-143,540
| -88% | -$6.67M | ﹤0.01% | 3224 |
|
|
2014
Q4 | $4.87M | Buy |
162,430
+31,890
| +24% | +$1.29M | ﹤0.01% | 1725 |
|
|
2014
Q3 | $5.22M | Sell |
130,540
-105,420
| -45% | -$4.71M | 0.01% | 1735 |
|
|
2014
Q2 | $11.8M | Sell |
235,960
-24,840
| -10% | -$1.56M | 0.01% | 1028 |
|
|
2014
Q1 | $15.6M | Buy |
260,800
+74,330
| +40% | +$4.93M | 0.02% | 842 |
|
|
2013
Q4 | $9.32M | Buy |
186,470
+20,250
| +12% | +$1.06M | 0.01% | 1306 |
|
|
2013
Q3 | $8.31M | Sell |
166,220
-2,160
| -1% | -$145K | 0.01% | 1288 |
|
|
2013
Q2 | $13M | Buy |
+168,380
| New | +$13.7M | 0.02% | 890 |
|
Barclays's ARNA Position: Q1 2022 in Review
Barclays sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 149,859 shares — an estimated $13.9M sold.
Barclays first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $13.9M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Barclays reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Barclays sold 149,859 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $13.9M.
- Barclays first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Barclays's Arena Pharmaceuticals Inc position peaked at $13.9M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Barclays's 13F filing for Q1 2022, filed 16 May 2022.